21.50k followers • 14 symbols Watchlist by TREA
Follow this list to discover and track the stock of publicly traded companies with COVID-19 related treatment and healthcare plans.
Curated by TREA
|Watchlist||Change today||1-month return||1-year return||Total return|
|The Fight Against COVID19||-1.37%||-||-||-|
|Symbol||Company name||Last price||Change||% change||Market time||Volume||Avg vol (3-month)||Market cap|
|JNJ||Johnson & Johnson||172.18||-||-||4:00 pm GMT-4||4.09M||6.66M||453.42B|
|PFE||Pfizer Inc.||42.79||-0.27||-0.63%||4:03 pm GMT-4||28.70M||25.82M||239.53B|
|ABBV||AbbVie Inc.||118.87||+0.32||+0.27%||4:02 pm GMT-4||4.48M||6.35M||209.95B|
|MRNA||Moderna, Inc.||345.64||-3.68||-1.05%||4:00 pm GMT-4||10.10M||12.95M||138.78B|
|SNY||Sanofi||51.53||-0.53||-1.02%||4:00 pm GMT-4||1.92M||1.34M||129.09B|
|GSK||GlaxoSmithKline plc||40.1||+0.60||+1.52%||4:00 pm GMT-4||5.34M||4.30M||100.89B|
|GILD||Gilead Sciences, Inc.||69.83||-0.23||-0.33%||4:00 pm GMT-4||6.95M||6.72M||87.58B|
|BNTX||BioNTech SE||312.59||-0.86||-0.27%||4:00 pm GMT-4||4.06M||3.24M||75.50B|
|REGN||Regeneron Pharmaceuticals, Inc.||583.13||-3.28||-0.56%||4:00 pm GMT-4||361.43k||752.26k||62.13B|
|TAK||Takeda Pharmaceutical Company Limited||16.93||-0.20||-1.17%||4:00 pm GMT-4||2.70M||2.03M||53.38B|
|NVAX||Novavax, Inc.||184||-5.01||-2.65%||4:00 pm GMT-4||2.41M||4.22M||13.63B|
|VIR||Vir Biotechnology, Inc.||36.39||-0.66||-1.78%||4:00 pm GMT-4||479.16k||720.05k||4.73B|
|INO||Inovio Pharmaceuticals, Inc.||8.5||-0.17||-1.96%||4:00 pm GMT-4||2.20M||5.40M||1.78B|
Dr. Anand Swaminathan, Emergency Medicine Physician in New Jersey, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.
Emergent BioSolutions said it will resume production of Johnson & Johnson's COVID-19 vaccine at its troubled Baltimore facility, where operations were stopped in April after millions of doses were found to be contaminated. Last week, J&J slashed 2021 production target of its single-dose vaccine to between 500 million and 600 million doses from its original goal to produce a billion shots. The resumption follows additional reviews and collaboration with the FDA and manufacturing partners, Emergent Chief Executive Officer Robert Kramer said.
LONDON, July 29, 2021--GSK announces FDA approval for Nucala (mepolizumab) for use in adults with chronic rhinosinusitis with nasal polyps.